SANTA CLARA, Calif., May 6 /PRNewswire/ -- Galileo Pharmaceuticals, Inc. today announced promotions of president and chief financial officer Lloyd Kunimoto to chief executive officer, and senior vice president Dr. David Liebowitz to chief scientific officer and executive vice president, research and development. Dr. David Milligan of Bay City Capital was appointed Chairman of the Board of Directors, replacing Dr. Guy Miller, who leaves Galileo to become chairman and chief executive officer of Edison Pharmaceuticals, a subsidiary of Galileo, focused on the treatment of mitochondrial diseases. Dr. Miller remains a member of Galileo's Board of Directors.
In addition, the company announced the recent appointments of three new vice presidents, Dr. Daniel Chu, vice president, medicinal chemistry, Dr. Gregory Wagner, vice president, preclinical development, and Dr. Drew S. Jones, vice president, clinical and regulatory affairs. Each vice president brings more than 15 years of large pharmaceutical experience to Galileo accelerate the company's proprietary platform through clinical development.
"Since joining the company less than one year ago, Lloyd and Dave have shown tremendous leadership in accelerating the drug discovery capabilities of Galileo's Conserved Inflammatory Pathway (CIP) Modulator platform to identify proprietary lead compounds which may be useful in treating disorders where inflammation plays a critical role," stated David Milligan, Chairman of the Board, Galileo Pharmaceuticals, Inc. and vice president, Bay City Capital. "In addition, we extend our thanks to Guy for his years of dedication and service to the company."
"In the last year, we have streamlined the company's novel discovery platform on the generation of compounds for arthritis, asthma, diabetes and other diseases where inflammatory pathways play a critical role, such as cancer," said Lloyd Kunimoto, chief executive officer of Galileo Pharmaceuticals, Inc. "With our focused pipeline of development candidates and an accomplished, experienced new management team in place to move them forward effectively, Galileo is poised to execute on our strategic initiatives in the years ahead.
"We intend to file one internally-generated Investigational New Drug application each year beginning next year, and expect our partners to move a number of Galileo compounds into development," continued Mr. Kunimoto. "In addition, we expect to sign a new pharmaceutical partnership focused on the clinical development of our lipoxygenase inhibitors, which are our most advanced internal programs. Achieving these milestones will demonstrate our ability to build a valuable drug pipeline."
Dr. David V. Milligan joined the Board of Directors in December 2001 and was elected chairman in 2005. Dr. Milligan retired from Abbott Laboratories in 1996 as senior vice president and chief scientific officer. He is currently a vice president and business advisory board member for Bay City Capital, a San Francisco-based merchant bank. Dr. Milligan is non-executive vice-chairman of Caliper Life Sciences as well as a director of ICOS Corporation, Pathway Diagnostics, Reliant Pharmaceuticals and Vicuron Pharmaceuticals. He is a member of the Princeton University chemistry department advisory board and the University of Illinois School of Chemical Sciences leadership council. Dr. Milligan holds an AB in Chemistry, summa cum laude, from Princeton University as well as M.S. and Ph.D. degrees in organic chemistry from the University of Illinois.
Lloyd Kunimoto joined Galileo Pharmaceuticals, Inc. as president and chief financial officer in May 2004 from Epicyte Pharmaceutical Inc. At Epicyte he served as the chief executive officer, leveraging Epicyte's antibody manufacturing technology and building a product-based biopharmaceutical company. Prior to Epicyte, Mr. Kunimoto was senior vice president, corporate development at Exelixis, Inc., where he was responsible for business development, intellectual property and mergers and acquisitions. Prior to Exelixis, he was vice president, commercial development at Monsanto, and president and chief executive officer at Calgene, Inc., a public biotechnology company that was acquired by Monsanto. Mr. Kunimoto holds a B.S. in mathematics from Stanford University.
Dr. David Liebowitz joined Galileo Pharmaceuticals, Inc. as senior vice president, research and development in April 2004 from Amgen, Inc. At Amgen he served as the director, research responsible for all oncology drug discovery and development programs at the Amgen's Washington research site. He joined Amgen with the acquisition of Immunex where he was the oncology research therapeutic area head. Prior to joining Immunex, Dr. Liebowitz was an associate investigator in the Abramson Cancer Institute at the University of Pennsylvania and served as director of their immunotherapy programs. He was also an assistant professor of medicine and virology at the University of Chicago, where he was the director of the bone marrow transplant program. Dr. Liebowitz has B.S. and M.S. degrees in biology from Emory University, and an M.D. and Ph.D. in molecular genetics and cell biology from the University of Chicago.
Dr. Daniel Chu joins Galileo Pharmaceuticals, Inc. as vice president, medicinal chemistry. He brings over thirty years of medicinal chemistry expertise to Galileo, having held key positions at Anacor, Chiron Corporation, Kosan Biosciences, and Abbott Laboratories. Dr. Chu received his B.S. in chemistry from the University of Alberta, and his Ph.D. in organic chemistry from University of New Brunswick. Dr. Chu is the author and co-author of more than 115 research papers and has been awarded over 60 U.S. patents. He is the inventor of four marketed quinolone antibacterial agents.
Dr. Wagner joined Galileo Pharmaceuticals as vice president, preclinical development. He brings over 15 years of pharmacology, toxicology and preclinical development expertise from several biotechnology and drug development companies, including Sugen, Rigel and Kosan Biosciences. During this time he was responsible for conducting the preclinical programs and subsequent preparation of numerous successful IND and NDA submissions. Dr. Wagner holds a Ph.D. in pharmacology & toxicology, and is a diplomat of the American Board of Toxicology.
Dr. Drew S. Jones joined Galileo Pharmaceuticals, Inc. as vice president, clinical and regulatory affairs. He brings extensive experience in developing and implementing clinical trials across a broad spectrum of disease indications, having held escalating positions within Alza Corporation, Johnson & Johnson's Pharmaceutical Research Foundation, and Janssen Research Foundation. Dr. Jones holds a B.A. from Duke University, B.S.P.H. and M.P.H. degrees from the University of North Carolina and an M.D. from East Carolina University School of Medicine.
About Galileo Pharmaceuticals, Inc.
Galileo is focused on the discovery and development of small molecule therapeutics to treat metabolic diseases and other disorders mediated by inflammation. Leveraging our novel discovery platform based on the conserved inflammatory pathway (CIP) modulators in plants, we are developing a pipeline of novel therapeutics for the treatment arthritis, asthma, cardiovascular disease, diabetes and other diseases mediated by inflammation. We have identified potent, selective modulators of therapeutically important target classes such as kinases, lipoxygenases and PPAR modulators, and our results to date indicate that our discovery platform will enable us to approach these important target classes. For more information about Galileo Pharmaceuticals, Inc., please visit http://www.galileopharma.com/.
Lloyd Kunimoto Angela Bitting
President and CEO Bitting Communications
Galileo Pharmaceuticals, Inc. +1-925-462-1106
+1-408-654-5830 ext. 123 firstname.lastname@example.org@galileopharma.com
Galileo Pharmaceuticals, Inc.